← Back to Search

Unknown

JV-GL1 for Ocular Hypertension

Phase 1 & 2
Waitlist Available
Led By David Wirta, MD
Research Sponsored by JeniVision, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to day 28 of treatment
Awards & highlights

Study Summary

This trial will test if a new drug can safely lower eye pressure in people with glaucoma.

Eligible Conditions
  • Ocular Hypertension
  • Open-Angle Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to day 28 of treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to day 28 of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Intraocular Pressure (IOP)

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Randomized Part 2, Arm 2Experimental Treatment1 Intervention
Dose 2 selected in Part I
Group II: Randomized Part 2, Arm 1Experimental Treatment1 Intervention
Dose 1 selected in Part I
Group III: Randomized Part 2, Arm 3Active Control1 Intervention

Find a Location

Who is running the clinical trial?

JeniVision, Inc.Lead Sponsor
David Wirta, MDPrincipal InvestigatorEye Research Foundation, Inc.
3 Previous Clinical Trials
718 Total Patients Enrolled
1 Trials studying Ocular Hypertension
77 Patients Enrolled for Ocular Hypertension

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What medical conditions have JV-GL1 been demonstrated to improve?

"JV-GL1 is a common glaucoma medication used to treat open angle glaucoma (OAG). Additionally, JV-GL1 can be beneficial in addressing increased intra ocular pressure (IOP), inadequate reaction to other treatments, and chronic angle closure glaucoma with preceeding peripheral iridotomy or laser iridoplasty."

Answered by AI

Is this trial actively seeking participants at present?

"The listing on clinicaltrials.gov indicates that recruitment for this particular medical trial has been closed since March 28th 2022, and it first appeared on the website in mid-March 2021. Though inactive, there are 951 other active trials currently recruiting subjects."

Answered by AI

Is there precedent for this experiment, or is it a pioneering venture?

"At the present time, 11 ongoing trials are assessing JV-GL1 in 17 cities and 7 countries. This therapeutic was initially trialled back in 2013 by Synphora AB, with Phase 2 drug approval being reached after 100 patients were enrolled. Since then a further 138 studies have been completed."

Answered by AI

What is the aggregate number of individuals engaging in this clinical experiment?

"At the moment, this trial is not looking for additional candidates. According to its posting date from March 10th 2021 and last edit on March 28th 2022, it has been concluded. However, there are still 940 studies seeking patients with glaucoma symptoms as well as 11 trials that require individuals suffering from JV-GL1 specifically."

Answered by AI

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
Eye Research Foundation
What portion of applicants met pre-screening criteria?
Met criteria
~17 spots leftby Mar 2025